169 PazoDoble – Pazopanib vs. Pazopanib plus Gemcitabine in relapsed or metastatic uterine leiomyosarcomas or uterine carcinosacomas

LA Otten; J Sehouli; EM Grischke; D Pink; P Reichardt; P Harter; P Wimberger; Z Alwafai; IB Runnebaum; A Mustea

doi:10.1136/ijgc-2021-ESGO.253

Article info

Miscellaneous

169 PazoDoble – Pazopanib vs. Pazopanib plus Gemcitabine in relapsed or metastatic uterine leiomyosarcomas or uterine carcinosacomas

Free

Authors

LA Otten Universitätsklinikum Bonn, Klinik für Gynäkologie und Gynäkologische Onkologie PubMed articles Google scholar articles
J Sehouli Universitätsmedizin Berlin Charité Campus Virchow-Klinikum PubMed articles Google scholar articles
EM Grischke Universitätsfrauenklinik Tübingen PubMed articles Google scholar articles
D Pink Helios Klinikum Bad Saarow, Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum PubMed articles Google scholar articles
P Reichardt Helios Klinikum Berlin-Buch, Klinik für Onkologie und Paliativmedizin PubMed articles Google scholar articles
P Harter Ev. KlinikenEssen-Mitte, Department of Gynecology and Gynecologic Oncology PubMed articles Google scholar articles
P Wimberger Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden, Klinik für Frauenheilkunde und Geburtshilfe PubMed articles Google scholar articles
Z Alwafai Universitätsmedizin Greifswald, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe PubMed articles Google scholar articles
IB Runnebaum Universitätsklinikum Jena PubMed articles Google scholar articles
A Mustea Universitätsklinikum Bonn, Klinik für Gynäkologie und Gynäkologische Onkologie PubMed articles Google scholar articles

Citation

Otten L, Sehouli J, Grischke E, et al

169 PazoDoble – Pazopanib vs. Pazopanib plus Gemcitabine in relapsed or metastatic uterine leiomyosarcomas or uterine carcinosacomas

International Journal of Gynecologic Cancer 2021;31:A153-A154.

Publication history

First published October 12, 2021.

Online issue publication

January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password